Additionally, COMP levels were increased in patients with fibrosis stage ≥ F2 [11 (5) vs. 8.9 (4.7); P < 0.001] or fibrosis stage ≥ F3 [11.8 (6.5) vs. 9.3 (4.9); P < 0.001], as well as in cirrhotic [13.7 (7.9) vs. 9.3 (7.9); P < 0.001] and HCC patients [14 (16.3) vs. 10.2 (6); P = 0.028]. Here, COMP is linked to hepatocellular carcinoma.